News
FDA approves glofitamab for DLBCL
Glofitamab, a T cell–engaging bispecific antibody, has been approved by the Food and Drug Administration for adults with DLBCL.
News
Increased cancer in military pilots and ground crew: Pentagon
But military aircrew and ground crew were less likely to die from cancer, compared with the U.S. population.
News
Europe approves first gene therapy for hemophilia B
Exorbitantly priced gene therapy to treat hemophilia B has been approved for sale across the European Union and European Economic Area.
News
FDA approves once-weekly hemophilia A product
Newly approved by the FDA, this replacement therapy for a rare bleeding disorder has been found to reduce both dosing frequency and bleeds.
News
FDA approves first-in-class drug for follicular lymphoma
New treatment for relapsed/refractory follicular lymphoma, newly approved by the FDA, showed effectiveness in research presented at ASH 2022.
News
FDA approves olutasidenib for some AML patients
Olutasidenib has been green-lighted by the FDA for treatment of some patients with acute myeloid leukemia.
News
FDA rejects poziotinib for certain types of lung cancer
The clinical data the company submitted was deemed insufficient for approval.
News
Atezolizumab (Tecentriq) bladder cancer indication withdrawn in United States
The anti-PD-L1 inhibitor continues to be approved for lung and liver cancers and melanoma.
News
Blenrep for multiple myeloma withdrawn from U.S. market
As requested by the U.S. Food and Drug Administration, the multiple myeloma drug blenrep is being taken off the market after disappointing results...
News
FDA approves futibatinib (Lytgobi) for certain biliary tract cancers
Futibatinib is “a key example of the potential of precision medicine” in intrahepatic cholangiocarcinoma.
News
First drug therapy approved for childhood GVHD
FDA greenlights ibrutinib for child blood cancer patients with chronic graft-versus-host disease.
News
Oncologists’ wealth and debt: COVID had little impact
Oncologists’ income rose, on average, by 2% in the past year and now stands at an average of $411,000 annually.
News
FDA approves Enhertu (trastuzumab deruxtecan) for HER2 lung cancer
“These results establish the new standard of care for patients with NSCLC harboring HER2 mutations.”
News
Oncologists flock to Chicago for ASCO, after 2 years online
The theme of the 2022 meeting is advancing equitable cancer care through innovation.